Differential subtypes of diabetic older adults diagnosed with Alzheimer's disease

Geriatrics and Gerontology International

Volumn 14, Issue SUPPL2, 2014, Pages 62-70

  Sakurai, Takashi ^a   Kawashima, Shuji ^a   Satake, Shosuke ^a   Miura, Hisayuki ^a   Tokuda, Haruhiko ^b   Toba, Kenji ^a  

^a Center for Comprehensive Care and Research on Memory Disorders   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Behavioral and psychological symptoms of dementia; Diabetes; Glycemic control; Pathophysiology

Indexed keywords

25 HYDROXYVITAMIN D; ADIPONECTIN; APOLIPOPROTEIN E4; BIGUANIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERGLYCEMIC AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM ALBUMIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; APATHY; ARTICLE; BARTHEL INDEX; BLOOD LEVEL; BRAIN PERFUSION; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DAILY LIFE ACTIVITY; DAYTIME SOMNOLENCE; DEMOGRAPHY; DIABETIC ANGIOPATHY; DIABETIC PATIENT; DIARRHEA; DISEASE ASSOCIATION; DYSPHAGIA; FEMALE; GERIATRIC DEPRESSION SCALE; GERIATRIC DISORDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERPHAGIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERNUTRITION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINE INCONTINENCE; VERY ELDERLY; VITAMIN BLOOD LEVEL; BLOOD; BRAIN; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SCINTISCANNING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84896537382     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12250     Document Type: Article

References (56)

1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
2. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565-1572.
3. Rizzo MR, Marfella R, Barbieri M etal. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 2010; 33: 2169-2174.
4. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. Nutr Health Aging 2006; 10: 293-295.
5. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, ApoE gene, and the risk for dementia and related pathologies. The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-1262.
6. Matsuzaki T, Sasaki K, Tanizaki Y etal. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75: 764-770.
7. Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 1997; 49: 1306-1311.
8. Beeri MS, Silverman JM, Davis KL etal. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005; 60: 471-475.
9. Sonnen JA, Larson EB, Brickell K etal. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009; 66: 315-322.
10. Ahtiluoto S, Polvikoski T, Peltonen M etal. Diabetes, Alzheimer disease, and vascular dementia. A population-based neuropathologic study. Neurology 2010; 75: 1195-1202.
11. Mielke MM, Rosenberg PB, Tschanz J etal. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69: 1850-1858.
12. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B, REAL.FR Study Group. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 2009; 73: 1359-1366.
13. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 2006; 67: 1357-1362.
14. Helzner EP, Luchsinger JA, Scarmeas N etal. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66: 343-348.
15. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud 1988; 10: 64-67.
16. Kawai Y, Miura R, Tujimoto M etal. Neuropsychological differentiation of Alzheimer's disease and dementia with Lewy bodies in a memory clinic. Psychogeriatrics 2013; 13: 157-163.
17. McKhann G, Drachman D, Folstein M etal. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
18. Kojima T, Akishita M, Nakamura T etal. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 2012; 12: 425-430.
19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
21. Mohs R, Rosen W, Davis K. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19: 448-450.
22. Raven JC, Court JH, Raven J. Manual for Raven's Progressive Matrices and Vocabulary Scales, The Coloured Progressive Matrices. London: HK Lewis, 1977.
23. Wechsler D. Wechsler Memory Scale-Revised. San Antonio, TX: Psychological Corp, 1981.
24. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55: 1621-1626.
25. Yesavage JA, Brink T, Rose T etal. Development and validation of a geriatric depression screening scale. J Psychiatr Res 1983; 17: 37-49.
26. Baumgarten M, Becker R, Gauthier S. Validity and reliability of the dementia behavior disturbance scale. J Am Geriatr Soc 1990; 38: 221-226.
27. Zarit S, Reever K, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-655.
28. Ishimoto Y, Wada T, Kasahara Y etal. Fall Risk Index predicts functional decline regardless of fall experiences among community-dwelling elderly. Geriatr Gerontol Int 2012; 12: 659-666.
29. Kataoka S, Paidi M, Howard BV. Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem 1994; 40: 11-13.
30. Su Z, Slay BR, Carr R, Zhu Y. The recognition of 25-hydroxyvitamin D2 and D3 by a new binding protein based 25-hydroxyvitamin D assay. Clin Chim Acta 2013; 417: 62-66.
31. Hayama S, Higuchi T, Miyakoshi H, Nakano Y. Analytical evaluation of a high-molecular-weight (HMW) adiponectin chemiluminescent enzyme immunoassay. Clin Chim Acta 2010; 411: 2073-2078.
32. Admiraal-Behloul F, van den Heuvel DM, Olofsen H etal. Fully automatic segmentation of white matter hyperintensities in MR images of the elderly. Neuroimage 2005; 28: 607-617.
33. Nihashi T, Yatsuya H, Hayasaka K etal. Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat Med 2007; 25: 255-262.
34. Burdette J, Minoshima S, Borght TV, Tran DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotactic surface projections. Radiology 1996; 198: 837-843.
35. Ikeda M, Brown J, Holland A, Fukuhara R, Hodges J. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73: 371-376.
36. Bhagavati S. Marked hyperphagia associated with total loss of satiety in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2008; 20: 248-249.
37. Amitani M, Asakawa A, Amitani H, Inui A. The role of leptin in the control of insulin-glucose axis. Front Neurosci 2013; 7: 51.
38. Rothman RL, Mulvaney S, Elasy TA etal. Self-management behaviors, racial disparities, and glycemic control among adolescents with type 2 diabetes. Pediatrics 2008; 121: e912-e919.
39. Hanlon EC, Van Cauter E. Quantification of sleep behavior and of its impact on the cross-talk between the brain and peripheral metabolism. Proc Natl Acad Sci U S A 2011; 108 (Suppl 3): 15609-15616.
40. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 2013; 33: 659-674.
41. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-825.
42. Kostoglou-Athanassiou I, Athanassiou P, Gkountouvas A, Kaldrymides P. Vitamin D and glycemic control in diabetes mellitus type 2. Ther Adv Endocrinol Metab 2013; 4: 122-128.
43. Heidemann C, Sun Q, van Dam RM etal. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008; 149: 307-316.
44. Morley JE, Malmstrom TK. Frailty, sarcopenia, and hormones. Endocrinol Metab Clin North Am 2013; 42: 391-405.
45. Krentz AJ, Viljoen A, Sinclair A. Insulin resistance: a risk marker for disease and disability in the older person. Diabet Med 2013; 30: 535-548.
46. Farrer LA, Cupples LA, Haines JL etal. APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997; 278: 1349-1356.
47. Bonte FJ, Harris TS, Hynan LS, Bigio EH, White CL, 3rd. Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation. Clin Nucl Med 2006; 31: 376-378.
48. Fukazawa R, Hanyu H, Sato T etal. Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord 2013; 35: 280-290.
49. Togo T, Isojima D, Akatsu H etal. Clinical features of argyrophilic grain disease: a retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry 2005; 13: 1083-1091.
50. Braak H, Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 1998; 105: 801-819.
51. Tolnay M, Clavaguera F. Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 2004; 24: 269-283.
52. Brown AF, Mangione CM, Saliba D etal. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51 (5 Suppl Guidelines): S265-S280.
53. Qaseem A, Vijan S, Snow V etal. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007; 147: 417-422.
54. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci 2001; 56: M5-13.
55. Sinclair AJ, Paolisso G, Castro M etal. European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diab Metab 2011; 37: S27-38.
56. Araki A, Ito H. Diabetes mellitus and geriatric syndromes. Geriatr Gerontol Int 2009; 9: 105-114.